This Morning's Technical Outlook on Generic Drugs Stocks -- Versartis, Akorn, Rigel Pharma, and Medicines

NEW YORK, Dec. 13, 2017 /PRNewswire/ -- In keeping with the commitment to dynamically provide members with timely information, WallStEquities.com has issued free tailored Stock Review on VSAR, AKRX, RIGL, and MDCO which is a click away at www.wallstequities.com/registration.  WallStEquities.com revisits the Generic Drugs market, which can be segmented into biosimilars, simple generic, and super generic. The cost-effectiveness of generic drugs has given it a competitive advantage over branded drugs in the market, as they are governed by the same governing framework as the latter. Under evaluation for today are the following stocks: Versartis Inc. (NASDAQ: VSAR), Akorn Inc. (NASDAQ: AKRX), Rigel Pharmaceuticals Inc. (NASDAQ: RIGL), and The Medicines Co. (NASDAQ: MDCO). With Wall St. Equities' free research reports get an edge over stock markets, sign up now at:

www.wallstequities.com/registration

Versartis

Menlo Park, California headquartered Versartis Inc.'s shares plummeted 7.06%, closing Tuesday's trading session at $1.98. The stock recorded a trading volume of 1.27 million shares. The Company's shares have advanced 11.27% in the last month. The stock is trading 8.97% below its 50-day moving average. Additionally, shares of Versartis, which operates as an endocrine-focused biopharmaceutical company in the US, have a Relative Strength Index (RSI) of 45.90. Our free and thorough report on VSAR awaits you at:

www.wallstequities.com/registration/?symbol=VSAR

Akorn

On Tuesday, shares in Lake Forest, Illinois headquartered Akorn Inc. recorded a trading volume of 2.54 million shares, which was above their three months average volume of 2.21 million shares. The stock declined 1.35%, ending the day at $32.20. The Company's shares have surged 47.50% on an YTD basis. The stock is trading above its 200-day moving average by 1.56%. Furthermore, shares of Akorn, which develops, manufactures, and markets specialized generic and branded pharmaceuticals, over-the-counter drug products, and animal health products in the US and internationally, have an RSI of 37.71.  AKRX's complimentary research coverage is a few simple steps away at:

www.wallstequities.com/registration/?symbol=AKRX

Rigel Pharmaceuticals

South San Francisco, California-based Rigel Pharmaceuticals Inc.'s stock finished the day 1.90% lower at $3.61. A total volume of 3.71 million shares was traded, which was above their three months average volume of 1.84 million shares. The Company's shares have surged 47.95% in the previous three months and 51.68% on an YTD basis. The stock is trading above its 200-day moving average by 22.60%. Additionally, shares of Rigel Pharma, which engages in the discovery and development of drugs in the therapeutic areas of immunology, oncology, and immuno-oncology, have an RSI of 40.40.

On December 08^th, 2017, Rigel Pharma (RIGL) announced that on December 04^th, 2017, the Compensation Committee of the Company's Board of Directors approved the grant of inducement stock options to purchase an aggregate of 60,000 shares of common stock to one new employee. This award was granted pursuant to the Company's Inducement Plan, as amended, as an inducement material to the new employee entering into employment with RIGL, in accordance with NASDAQ Listing Rule 5635(c)(4). Register for your free research report on RIGL at:

www.wallstequities.com/registration/?symbol=RIGL

Medicines

Shares in Parsippany, New Jersey-based The Medicines Co. ended yesterday's session 4.85% higher at $27.26. The stock recorded a trading volume of 2.14 million shares, which was above its three months average volume of 1.23 million shares. The Company's shares are trading 14.11% below their 50-day moving average. Moreover, shares of Medicines Co., which provides medicines for patients in acute and intensive care hospitals worldwide, have an RSI of 33.12.

On November 29^th, 2017, Medicines Co. announced that it has entered into a definitive agreement to sell its infectious disease business unit to Melinta Therapeutics, Inc. (MLNT) for $270 million in upfront consideration and guaranteed payments ($215 million of guaranteed cash and $55 million of MLNT common stock), tiered royalty payments of 5% to 25% on worldwide net sales of Vabomere™, Orbactiv®, and Minocin IV, and the assumption by MLNT of all royalty, milestone, and other payment obligations relating to those products. Wall St. Equities' downloadable research report on MDCO available at:

www.wallstequities.com/registration/?symbol=MDCO

--

Wall St. Equities:

Wall St. Equities (WSE) produces regular sponsored and non-sponsored reports, articles, stock market blogs, and popular investment newsletters covering equities listed on NYSE and NASDAQ and micro-cap stocks. WSE has two distinct and independent departments. One department produces non-sponsored analyst certified content generally in the form of press releases, articles and reports covering equities listed on NYSE and NASDAQ and the other produces sponsored content (in most cases not reviewed by a registered analyst), which typically consists of compensated investment newsletters, articles and reports covering listed stocks and micro-caps. Such sponsored content is outside the scope of procedures detailed below.

WSE has not been compensated; directly or indirectly; for producing or publishing this document.

PRESS RELEASE PROCEDURES:

The non-sponsored content contained herein has been prepared by a writer (the "Author") and is fact checked and reviewed by a third-party research service company (the "Reviewer") represented by a credentialed financial analyst [for further information on analyst credentials, please email [email protected]. Rohit Tuli, a CFA® charterholder (the "Sponsor"), provides necessary guidance in preparing the document templates. The Reviewer has reviewed and revised the content, as necessary, based on publicly available information which is believed to be reliable. Content is researched, written and reviewed on a reasonable-effort basis. The Reviewer has not performed any independent investigations or forensic audits to validate the information herein. The Reviewer has only independently reviewed the information provided by the Author according to the procedures outlined by WSE. WSE is not entitled to veto or interfere in the application of such procedures by the third-party research service company to the articles, documents or reports, as the case may be. Unless otherwise noted, any content outside of this document has no association with the Author or the Reviewer in any way.

NO WARRANTY

WSE, the Author, and the Reviewer are not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted whatsoever for any direct, indirect or consequential loss arising from the use of this document. WSE, the Author, and the Reviewer expressly disclaim any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Additionally, WSE, the Author, and the Reviewer do not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.

NOT AN OFFERING

This document is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed, and is to be used for informational purposes only. Please read all associated disclosures and disclaimers in full before investing. Neither WSE nor any party affiliated with us is a registered investment adviser or broker-dealer with any agency or in any jurisdiction whatsoever. To download our report(s), read our disclosures, or for more information, visit

https://wallstequities.com/legal-disclaimer/

CONTACT

For any questions, inquiries, or comments reach out to us directly. If you're a company, we are covering and wish to no longer feature on our coverage list contact us via email and/or phone between 09:30 EDT to 16:00 EDT from Monday to Friday at: 
Email: [email protected] 
Phone number: +21-32-044-483
Office Address: 1 Scotts Road #24-10, Shaw Center Singapore 228

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.

SOURCE Wall St. Equities

Related Links

http://www.wallstequities.com